DE69726426D1 - Unterdrückung von immunantwort durch hemmung von cathepsin s - Google Patents

Unterdrückung von immunantwort durch hemmung von cathepsin s

Info

Publication number
DE69726426D1
DE69726426D1 DE69726426T DE69726426T DE69726426D1 DE 69726426 D1 DE69726426 D1 DE 69726426D1 DE 69726426 T DE69726426 T DE 69726426T DE 69726426 T DE69726426 T DE 69726426T DE 69726426 D1 DE69726426 D1 DE 69726426D1
Authority
DE
Germany
Prior art keywords
class
mhc
methods
immune response
cathepsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69726426T
Other languages
English (en)
Other versions
DE69726426T3 (de
DE69726426T2 (de
Inventor
L Ploegh
A Chapman
J Riese
R Wolf
Matthew S Bogyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Original Assignee
Brigham and Womens Hospital Inc
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21786243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69726426(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham and Womens Hospital Inc, Massachusetts Institute of Technology filed Critical Brigham and Womens Hospital Inc
Publication of DE69726426D1 publication Critical patent/DE69726426D1/de
Application granted granted Critical
Publication of DE69726426T2 publication Critical patent/DE69726426T2/de
Publication of DE69726426T3 publication Critical patent/DE69726426T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE69726426T 1996-04-22 1997-04-22 Unterdrückung von immunantwort durch hemmung von cathepsin s Expired - Fee Related DE69726426T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1810096P 1996-04-22 1996-04-22
US18100P 1996-04-22
PCT/US1997/006865 WO1997040066A1 (en) 1996-04-22 1997-04-22 Suppression of immune response via inhibition of cathepsin s

Publications (3)

Publication Number Publication Date
DE69726426D1 true DE69726426D1 (de) 2004-01-08
DE69726426T2 DE69726426T2 (de) 2004-09-16
DE69726426T3 DE69726426T3 (de) 2009-09-10

Family

ID=21786243

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726426T Expired - Fee Related DE69726426T3 (de) 1996-04-22 1997-04-22 Unterdrückung von immunantwort durch hemmung von cathepsin s

Country Status (12)

Country Link
US (4) US6608030B1 (de)
EP (1) EP0912601B2 (de)
JP (1) JP2000509376A (de)
AT (1) ATE255126T1 (de)
AU (1) AU723447B2 (de)
CA (1) CA2251714A1 (de)
DE (1) DE69726426T3 (de)
DK (1) DK0912601T4 (de)
ES (1) ES2208898T5 (de)
NZ (1) NZ332390A (de)
PT (1) PT912601E (de)
WO (1) WO1997040066A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204279B1 (en) * 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
WO1999037667A1 (en) * 1998-01-23 1999-07-29 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6387629B1 (en) * 1998-06-04 2002-05-14 Reprogen, Inc. Use of cathepsin S in the diagnosis and treatment of endometriosis
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
MXPA03001422A (es) 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles substituidos.
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
MXPA03001420A (es) 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles sustituidos.
MXPA03001421A (es) 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles sustituidos.
CA2421558A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. Method of monitoring the effect of cathepsin s inhibitors
EP1315741A2 (de) 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. Methode zum bekämpfen der allergien
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US6780985B2 (en) * 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
JP2003287139A (ja) * 2002-03-29 2003-10-10 Uchiyama Mfg Corp ガスケット
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
US7319016B1 (en) 2002-08-23 2008-01-15 Takeda San Diego, Inc. Crystallization of cathepsin S
BRPI0409868A (pt) * 2003-04-28 2006-05-16 Novartis Ag composição farmacêutica que compreende um inibidor da catepsina s e um opióide
CA2539053A1 (en) * 2003-09-23 2005-03-31 Merck Frosst Canada Ltd. Whole cell assay involving cathepsin s
US20070141059A1 (en) * 2003-12-11 2007-06-21 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
EP1697355A2 (de) * 2003-12-23 2006-09-06 Axys Pharmaceuticals, Inc. Amidinoverbindungen als cysteinproteaseinhibitoren
JP2007519744A (ja) * 2004-01-30 2007-07-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト システインプロテアーゼインヒビターとしてのシリナン化合物。
US9321838B2 (en) * 2006-04-10 2016-04-26 Fusion Antibodies Limited Therapy targeting cathepsin S
US20100266577A1 (en) * 2007-07-25 2010-10-21 Felipe Samaniego Method of Cancer Treatment with Antagonists of FAS Inhibitors
US20100331545A1 (en) * 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
CA2744888A1 (en) 2008-12-19 2010-06-24 Medivir Uk Ltd Cysteine protease inhibitors
US8859505B2 (en) 2010-06-16 2014-10-14 Medivir Uk Ltd Cysteine protease inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181925T1 (de) 1991-05-23 1999-07-15 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
JPH08502244A (ja) * 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
DE69321087T2 (de) 1992-12-25 1999-05-20 Mitsubishi Chem Corp Alpha-aminoketon Derivate
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
CA2216151A1 (en) 1995-03-24 1996-10-03 Arris Pharmaceutical Corporation Reversible protease inhibitors

Also Published As

Publication number Publication date
EP0912601B2 (de) 2008-11-05
AU2741897A (en) 1997-11-12
EP0912601A1 (de) 1999-05-06
DE69726426T3 (de) 2009-09-10
DK0912601T3 (da) 2004-03-29
DK0912601T4 (da) 2009-03-09
US20050095248A1 (en) 2005-05-05
ES2208898T3 (es) 2004-06-16
US7285525B2 (en) 2007-10-23
US20050080010A1 (en) 2005-04-14
EP0912601B1 (de) 2003-11-26
US6608030B1 (en) 2003-08-19
NZ332390A (en) 2000-07-28
ATE255126T1 (de) 2003-12-15
AU723447B2 (en) 2000-08-24
DE69726426T2 (de) 2004-09-16
PT912601E (pt) 2004-04-30
CA2251714A1 (en) 1997-10-30
WO1997040066A1 (en) 1997-10-30
JP2000509376A (ja) 2000-07-25
US7427591B2 (en) 2008-09-23
ES2208898T5 (es) 2009-04-16
US20030166534A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DK1731912T3 (da) Fremgangmåde til peptidselektion
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK0996726T3 (da) T-celle-membranprotein (TIRC7), peptider og antistoffer afledt deraf og anvendelse deraf
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN

8339 Ceased/non-payment of the annual fee